# Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

> **NCT02738632** · PHASE3 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 300 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Telmisartan/Amlodipine+Hydrochlorothiazide
- **DRUG:** Telmisartan/Amlodipine
- **DRUG:** Placebo for Hydrochlorothiazide

## Key facts

- **NCT ID:** NCT02738632
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738632, "Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02738632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*